Eli Lilly and GlaxoSmithKline-backed cancer treatment developer Turning Point Therapeutics has filed to raise up to $100m having secured $145m in VC funding.
Turning Point Therapeutics, a US-based precision oncology drug developer backed by pharmaceutical firms Eli Lilly and GlaxoSmithKline, has filed for a $100m initial public offering on the Nasdaq Global Market .
Founded in 2013 as TP Therapeutics, Turning Point has developed a pipeline of drug candidates for forms of cancer that have proven resistant to existing therapies. Its lead asset, repotrectinib, is aimed at non-small cell lung cancer and advanced solid tumours.
Repotrectinib is set to enter into a phase…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
